



MINI-REVIEW ERYTHROPOIETIN (EPO)

Bert Wognum, PhD | Senior Scientist

Introduction

The continuous formation of new red blood cells (RBCs) is regulated by the glycoprotein hormone erythropoietin (EPO). Human EPO was first purified in 1977 from 2500 liters of urine from aplastic anemia patients,¹ and the nucleotide sequence of the human EPO cDNA was reported in 1985.^{2,3} Since then, human EPO has become a major therapeutic agent to treat anemia of chronic renal failure and other diseases.⁴ The physiological role of EPO in stimulating the proliferation and survival of erythroid cells has been established for many years. More recently, EPO has also been observed to protect endothelial, neural, cardiac, and other cell types against cytotoxic damage. The purpose of this mini-review is to provide an overview of the physical properties and biological functions of EPO, and to describe methods of measuring EPO levels in biological fluids.

Structure of EPO

Human EPO consists of 165 amino acids and has a molecular mass of ~35,000 daltons. Approximately 40% of the molecular mass of the mature molecule is made up of 4 carbohydrate chains (3 N-linked and 1 O-linked).⁵ The carbohydrate moieties of EPO contain at least 10 molecules of sialic acid, which contribute to the relatively low (~4.4) iso-electric pH of EPO. EPO preparations are heterogeneous and contain multiple isoforms, which differ in their carbohydrate structure. Recombinant EPO produced in mammalian cells is fully glycosylated. Two forms of recombinant EPO, Epoietin-alpha and Epoietin-beta, are commonly used in the clinic. These molecules are produced in Chinese Hamster Ovary (CHO) cells and show differences in their carbohydrate structure and pharmacological properties, but not in clinical efficacy.⁶ The carbohydrate moiety is not essential for the biological activity of EPO in vitro, indicating that only the polypeptide is involved in binding to the EPO receptor. However, the in vivo biological activity of EPO is completely abolished when EPO is deglycosylated, suggesting that the carbohydrate moiety is important to prevent degradation and to delay clearance of EPO from the circulation. It is most likely that the carbohydrates are also needed during EPO biosynthesis and secretion.

Functions and Target Cells of EPO

Target cells for EPO have classically been identified by their ability to form hemoglobinized erythroid colonies after exposure of bone marrow or spleen cells to the hormone in clonal assays performed in methylcellulose-based media, such as MethoCult™, or in other semi-solid media.⁷ The earliest purely erythroid progenitor, the burst-forming unit erythroid (BFU-E), has a low sensitivity for EPO and requires additional factors, in particular Stem Cell Factor (SCF), for survival and proliferation.⁸ The more differentiated erythroid colony-forming unit (CFU-E) has a more limited proliferative potential than its precursor, the BFU-E, but is highly sensitive to EPO. The CFU-E and its progeny, down to the morphologically recognizable erythroblast stage, are absolutely dependent on EPO for survival,

proliferation and differentiation. However in some myeloproliferative disorders, in particular polycythemia vera, erythroid progenitor cells have acquired the capacity to proliferate, differentiate and survive in the absence of EPO.⁹ In serum-free liquid culture media (e.g. StemSpan™ H3000), EPO, in conjunction with SCF and other cytokines, can promote massive proliferation and erythroid differentiation of immature progenitors, resulting in almost pure erythroblast cultures, which upon switching to appropriate differentiation media, can mature into functional red blood cells.^{10,11}

EPO exerts its actions on red blood cell development through a single high affinity receptor,¹² which is expressed at relatively low levels (<1000 molecules) on erythroid cells between approximately the BFU-E and normoblast stages, but is absent from mature RBCs.¹³ The EPO receptor belongs to the class I cytokine receptor superfamily, which is a group of class I transmembrane proteins that shares certain structural features, in particular four conserved cysteine residues and the WSxWS motif in their extracellular domain. Other receptors of this group include the receptors for IL-2, IL-3, IL-6, G-CSF and thrombopoietin. Binding of EPO to the EPO receptor triggers dimerization, which induces tyrosine phosphorylation and activation of the intracellular JAK2 tyrosine kinase and a cascade of signaling events leading to induction of proliferation and other biological effects mediated by EPO. For reviews of signal transduction by the EPO receptor and related cytokine receptors, please see references 14 and 15.

EPO receptor expression has been reported in many non-hematopoietic cells, including myocytes, neuronal cells and endothelial cells.¹⁶⁻¹⁸ EPO is believed to have a physiological role in cardiac and brain development, as well as in protecting heart and brain tissue against inflammatory and ischemic damage, possibly through direct stimulation of cardiomyocytes and neural cells, or through mobilization of endothelial progenitor cells and promotion of neo-vascularization.

The actions of EPO and expression of functional EPO receptors on non-hematopoietic cells are not as clear as the role of EPO in erythropoiesis. While some studies reported EPO receptor expression on endothelial cells at levels as high as 27 000 molecules per cell,¹⁶ other studies reported that functional EPO receptors were expressed at much lower levels in endothelial, neural and other non-hematopoietic cells compared to erythroid cells, and not detectable using standard methods.^{19,20} One study reported that the tissue-protective effect of EPO in mice is not mediated through homodimerization of the EPO receptor, but through a hetero-receptor, containing the EPO receptor and the common beta-subunit of the IL-3, IL-5 and GM-CSF receptors (γc).²¹ However, other studies showed that the cytoprotective effect of EPO on neural and myocardial cells is mediated by the classical homodimeric EPO receptor and does not require expression of the γc subunit, which was undetectable on these cells.^{19,22,23}

EPO receptor expression and EPO-mediated effects on cell survival and growth have also been reported on primary human tumors and cultured



THE CELL EXPERTS™ | WWW.STEMCELL.COM

CATALOG #29013 | VERSION 3.0.0 | MAY 2011

TOLL-FREE T. 1 800 667 0322 • T. +1 604 877 0713 • TOLL-FREE F. 1 800 567 2899 • F. +1 604 877 0704

ORDERS@STEMCELL.COM • INFO@STEMCELL.COM • FOR FULL CONTACT DETAILS WORLDWIDE VISIT OUR WEBSITE

FOR RESEARCH USE ONLY. NOT FOR THERAPEUTIC OR DIAGNOSTIC USE.

MINI-REVIEW

tumor cell lines, which is a potential concern for the use of EPO to treat anemia in cancer patients. However, reports of EPO receptor (EPO-R) expression in tumor tissues and cell lines have been inconsistent and dependent on the types of reagents and detection methods used (see reference 24 for a recent review). In a recent study in which more than 200 human tumor cell lines were examined, EPO-R mRNA was detectable in most cell lines but at low levels. Few cell lines had detectable EPO-R protein expression (>100 molecules per cells), as measured using a monoclonal anti-EPO-R antibody or radiolabeled human recombinant EPO, while EPO receptors in those lines with detectable EPO-Rs appeared to be non-functional, even after exposure to EPO levels that were >100-fold higher than those needed to stimulate EPO-dependent hematopoietic cells.²⁵ In this respect non-hematopoietic and tumor cells appear to be relatively insensitive to EPO and in most studies exposure to very high EPO levels (between 0.5 U/mL and over 100 U/mL) was required for detectable effects on cell growth and survival.²⁴ In contrast, stimulation of the proliferation and differentiation of erythroid progenitor cells can be detected at much lower EPO levels, typically between 1 mU/mL and 1 U/mL, depending on the differentiation stage of the cells.⁷

EPO Production and Hypoxia

Most EPO is produced by peritubular interstitial cells in the renal cortex.²⁶ Small amounts of EPO mRNA have also been detected in the spleen, liver, lung, testis and brain. EPO production increases in response to tissue hypoxia, low arterial PO₂ and increased oxygen affinity of red blood cells. The hypoxic induction of EPO production is regulated at the transcriptional level by a transcription factor, Hypoxia-Inducible Factor (HIF-1), that binds to hypoxia response elements downstream of the EPO gene. HIF-1 is unstable in the presence of oxygen and can only be detected when oxygen is low.²⁷ HIF-1 thus acts as an oxygen sensor, which ensures that EPO production is increased when oxygen supply to the tissues is low and the demand for new red blood cells is high, while EPO production is shut down when red blood cell numbers and/or tissue oxygen supply returns to normal. This negative feedback mechanism ensures that RBC production is high enough to prevent anemia and maintain tissue oxygen supply at adequate levels, while not too high as to lead to polycythemia, and to elevated blood viscosity and cardiovascular risks.

EPO Levels Under Physiological and Pathological Conditions

Anemia

The normal range of EPO levels in human serum or plasma is in the order of 5-25 mU/mL, but EPO levels can be increased 100- to 1000-fold in response to hypoxia or blood loss. In healthy individuals and patients with various types of anemia (e.g. caused by blood loss, hemolysis, iron deficiency, aplastic bone marrow or by nutritional deficiencies), EPO levels are inversely correlated with hematocrit and hemoglobin levels, and reflect the reciprocal relation between oxygen supply and EPO production rate. However, EPO levels can be highly variable between patients at comparable degrees of anemia, as their anemic state is also determined by the rate of EPO consumption and by the activity of the erythroid progenitor compartment. In some disorders, EPO levels are much lower than expected from the degree of anemia. These disorders include chronic renal disease in which impaired renal EPO production is the primary cause of the anemia.²⁸ EPO levels are also disproportionately low in anemic patients with chronic disorders, such as rheumatoid arthritis, AIDS, and cancer. The mechanism of the anemia in these disorders is complex, but inhibition of EPO production and erythroid progenitor proliferation by inflammatory cytokines, such as IL-1 and TNF, is thought to be a major cause. Treatment

with recombinant EPO has been shown to be very effective in correcting the EPO deficiency and restoring red blood cell production in patients with chronic renal failure. Dependent on the underlying disease and endogenous EPO levels, EPO treatment has also been shown to be effective in correcting the anemia and reducing the need for blood transfusions in cancer and other diseases.

Polycythemia

Polycythemia vera (PV), or primary polycythemia, is a myeloproliferative disorder which is characterized by increased numbers of mature red blood cells.²⁹ An acquired mutation of the JAK2 tyrosine kinase (JAK2^{617F} mutant) in hematopoietic stem cells or progenitor cells is detectable in most PV patients. The mutation increases JAK2 kinase activity and confers EPO independence of erythroid progenitor growth.³⁰ EPO levels in PV patients are either low or within the normal range. In contrast to PV, secondary polycythemia or erythrocytosis is caused by EPO overproduction, which results in increased proliferation and maturation of normal erythroid progenitor cells. The EPO overproduction can be a normal physiological response to decreases in arterial oxygen saturation caused by respiratory or cardiac disorders, increased oxygen affinity of abnormal forms of hemoglobin, or low oxygen tension at high altitudes. EPO overproduction can also occur in the absence of hypoxia as a result of obstruction of local blood flow at the sites of EPO production in the kidney, or by EPO-producing renal or extra-renal tumors. EPO levels in blood of erythrocytosis patients are usually elevated, but can also be within the normal range, possibly as a result of higher EPO turnover rates and consumption by the expanded erythroid progenitor compartment. Erythrocytosis in healthy individuals can be the result of exposure to low oxygen tension at high altitude, or in some cases, as a result of injections with recombinant EPO or EPO analogs to boost athletic performance in sports (see below).

EPO Assays

Assays to measure EPO levels in serum, plasma and other biological fluids are important tools for diagnostic purposes, and for research into the role of EPO in various forms of anemia and polycythemia. There are three different types of erythropoietin assays: in vivo bioassays, in vitro bioassays and immunological assays.

In Vivo Bioassays

The classical in vivo bioassays for EPO are based on the stimulation of red blood cell formation by exogenous EPO in rats or mice in which the erythroid progenitor compartment has been expanded by hypoxia, bleeding or cytotoxic drugs. The erythroid response to injected EPO in these animals is typically measured by radioactive iron incorporation into spleen or blood cells. One of these assays, the exhypoxic polycythemic mouse assay,³¹ is still used as the reference standard for testing and calibrating EPO preparations and EPO assays. In vivo bioassays are laborious, require many animals and are generally not very sensitive. Their accuracy is also influenced by other compounds that can modify erythroid responses in vivo. These include, among others, steroid hormones, prostaglandins, metals (e.g. cobalt), and carbon monoxide. Because of the interference by non-EPO substances that stimulate erythropoiesis, in vivo bioassays are not useful for measuring EPO levels in serum, plasma or other biological fluids.

In Vitro Bioassays

In vitro bioassays for EPO measure EPO-induced stimulation of proliferation and/or differentiation of EPO-responsive cells in short-term cultures. Some assays measure erythroid colony formation in semi-solid culture media, using bone marrow as the source of EPO-responsive cells. Other assays measure EPO-induced stimulation of proliferation (usually measured by ³H-thymidine incorporation) or differentiation (measured by radioactive iron incorporation into hemoglobin) in suspension cultures in liquid media. Erythroid cells used in these cultures are typically derived from spleens of mice during the erythroid regeneration phase after injection with phenylhydrazine or other cytotoxic drugs, but bone marrow and fetal liver cells have been used as well.^{32,33} More recently, EPO-responsive tumor cell lines (e.g. the TF1 cell line, or cell lines engineered to express EPO-receptor cDNA) have been used as more convenient alternatives to primary cells.^{34,35} In vitro EPO bioassays are generally less laborious and more sensitive than in vivo assays. Like in vivo assays, they are not very suitable for measuring EPO levels in biological fluids since the EPO response of the cell can be modified by non-EPO components of serum and plasma. In one approach, this specificity problem has been addressed by selectively and quantitatively purifying EPO from test and standard samples by immuno affinity fractionation using an anti-EPO monoclonal antibody immobilized on magnetic particles, followed by testing of the eluted EPO in a proliferation assay.³⁶ The immuno affinity method can also be used to concentrate EPO from large sample volumes in order to increase the detection sensitivity and enable accurate measurement of normal and subnormal levels of biologically active EPO in biological fluids.

Immunological Assays

Immunoassays measure the binding of EPO to polyclonal or monoclonal antibodies against EPO. Their specificity and sensitivity is dependent on the specificity and affinity of the antibodies for EPO and on the assay format. Early EPO immunoassays used the radioimmunoassay (RIA) format in which EPO in test and standard samples was measured by competition with radioactively labeled EPO for binding to polyclonal rabbit anti-EPO antibodies. These assays were usually quite specific and sensitive, but also technically challenging due to the dependence on radioactively labeled EPO and the difficulty to separate bound and unbound EPO in a quantitative and reproducible manner.

Two-sided or sandwich immunoassays, which use antibodies against two different epitopes on the antigen, have now largely replaced the RIAs. In these assays, one antibody is immobilized on the surface of microwells or particles, while the other is conjugated to an enzyme or other label to detect the captured antigen. Depending on the type of label and substrate, the amount of EPO in test and standard preparations is usually measured by a colorimetric or chemiluminescent reaction. An example of this type of assay is the EPO ELISA provided by StemCell Technologies (see page 358).

Interpretation of EPO Measurements

In most EPO assays, the EPO concentration is measured by comparison to a range of standard preparations with known EPO concentration in the same assay. EPO standards are calibrated against reference EPO preparations, in particular, the Second International Reference Preparation of Human Urinary EPO or the International Standard for Recombinant-Derived EPO that are supplied by the World Health Organization (WHO) or the National Institute for Biological Standards and Control (NIBSC).³⁷ The unit of EPO is defined on the basis of EPO biological activity determined by in vivo bioassay (see the EPO International Unit box below for more information). Conventionally, EPO concentrations are expressed as milliunits per milliliter (mU/mL), even if immunoassays are used. Different

forms of EPO have different specific activities, and these differences can cause discrepancies between expected and measured results if EPO preparations of different origin, or results of different types of EPO assays, are compared. Human urinary EPO typically has a specific activity of ~70,000 U/mg of protein, while values reported for human recombinant EPO preparations are usually higher, ranging between 100,000 - 200,000 U/mg. The variability is mainly caused by differences in the carbohydrate composition of EPO from various sources, affecting the stability and thus activity of the EPO molecules in vivo, but not in vitro.³⁸ The carbohydrate structure of EPO does not affect the reactivity of EPO with anti-EPO monoclonal antibodies as the dose-response curves of human urinary and recombinant EPO in an EPO ELISA are parallel.³⁹

Immunoassays can be used to detect non-human EPO, but only if the non-human EPO is recognized by the anti-EPO antibodies used in the assay. Differences in immuno-reactivity of non-human EPO and human EPO may result in non-parallel dose response curves. In such cases, human EPO standards do not give reliable values for non-human EPO levels in test samples, and calibrated EPO standards from the same species as the test EPO should be used to get valid results.

EPO International Unit

The International Unit (U) of EPO activity is based on EPO measurements obtained using the exhypoxic polycythemic mouse assay or similar in vivo assays, and is defined as the amount of EPO that gives the same amount of erythroid stimulation as 5 micromoles of cobalt. Usually, EPO preparations are calibrated in bioassays or immunoassays against reference preparations, in particular the Second International Reference Preparation of urinary EPO, and the newer International Standard for Recombinant DNA-derived EPO (NIBSC-code 87-684).

Application of Anti-EPO Monoclonal Antibodies to Isolate and Detect Recombinant and Natural EPO

The ability of recombinant EPO to boost red blood cell production and thus increase aerobic capacity, has made it attractive as a performance-enhancing drug in competitive sports. Methods to detect EPO doping must distinguish exogenous recombinant EPO from endogenous natural EPO in human blood and urine. As EPO disappears rapidly from the circulation, these methods also need to be very sensitive and able to detect trace amounts of recombinant EPO before it completely disappears after cessation of treatment. The current EPO immunoassays detect natural and recombinant EPO with similar efficiency and thus cannot distinguish between recombinant and natural EPO. However, recombinant EPO produced in CHO cells is less acidic than endogenous, natural EPO, as a result of differences in carbohydrate structure. This difference forms the basis of tests to identify recombinant EPO and EPO analogs in blood and urine samples by isoelectric focusing, immunoblotting, and other analytical methods.^{40,41} Immunoaffinity isolation of EPO from test samples, using immobilized anti-EPO monoclonal antibodies, can increase the specificity and sensitivity of such detection methods by removing serum components that interfere with the accuracy of detection, and by concentrating trace amounts of EPO from large sample volumes.⁴²

Other Erythropoietic Molecules

Since the isolation and cloning of human EPO, several different types of new erythropoiesis-stimulating molecules have been developed. Darbepoetin is an engineered form of EPO that contains 5 N-linked glycosylation sites, compared to three for EPO, and as a result is more extensively glycosylated than EPO.⁴³ This molecule has a much longer half-life in the blood circulation than EPO itself and can be administered less frequently than EPO to be effective in patients.

Other modifications have also been shown to increase in vivo stability and/or activity of EPO. These include EPO conjugated to polyethylene glycol (pegylated EPO), EPO dimers and trimers, and synthetic molecules with similar but not identical polypeptide structures to EPO.⁴⁴ Chemical modification of lysine residues in EPO, through a process called carbamylation, completely abolishes the erythropoietic effects of EPO in vitro and in vivo. However, carbamylated EPO retains its ability to protect neural, cardiac, kidney and other tissues against hypoxia and other injuries.^{45,46}

In addition to modified forms of the EPO protein, several small peptide and non-peptide EPO mimetics have been developed. These synthetic molecules can bind to and activate the EPO receptor, and mimic the biological activity of EPO, while some have been shown to be effective in vivo.⁴⁷⁻⁵⁰ Stimulation of endogenous EPO production is another way to stimulate erythropoiesis in vivo. This stimulation can be achieved with synthetic compounds that stabilize HIF-1 or increase its binding to DNA through inhibition of the GATA-2 transcription factor, and thus increase transcription of the EPO gene, even in the presence of normal oxygen concentrations.⁵¹ EPO immunoassays and culture assays for hematopoietic and non-hematopoietic cells provide essential tools to test novel molecules and examine their stimulatory and potentially inhibitory actions or toxicity on erythroid and non-erythroid cell populations.

References

- Miyake T, et al., *J Biol Chem* 252: 5558-5564, 1977
- Jacobs K, et al., *Nature* 313: 806-810, 1985
- Lin FK, et al., *Proc Natl Acad Sci USA* 82: 7580-7584, 1985
- Eschbach JW, et al., *N Engl J Med* 316: 73-78, 1987
- Takeuchi M, et al., *Glycobiology* 1: 337-346, 1991
- Storring PL, et al., *Br J Haematol* 100: 79-89, 1998
- Gregory CJ, *J Cell Physiol* 89: 289-301, 1976
- Dai CH, et al., *Blood* 78: 2493-2497, 1991
- Weinberg RS, *Semin Hematol* 34: 64-69, 1997
- Giarratana MC, et al., *Nat Biotechnol* 23: 69-74, 2005
- Miharada K, et al., *Nat Biotechnol* 24: 1255-1256, 2006
- D'Andrea AD, et al., *Cell* 57: 277-285, 1989
- Wognum AW, et al., *Blood* 76: 697-705, 1990
- Damen JE, et al., *Exp Hematol* 24: 1455-1459, 1996
- Ihle JN, et al., *Ann N Y Acad Sci* 865: 1-611, 1998
- Anagnostou A, et al., *Proc Natl Acad Sci USA* 87: 5978-5982, 1990
- Ogilvie M, et al., *J Biol Chem* 275: 39754-69761, 2000
- Yu X, et al., *Development* 129: 505-516, 2002
- Um M, et al., *Cell Signal* 19: 634-645, 2007
- Sinclair AM, et al., *Blood* 115: 4264-4272, 2010
- Brines M, et al., *Proc Natl Acad Sci USA* 101: 14907-14912, 2004
- Sanchez PE, et al., *J Comp Neurol* 514: 403-414, 2009
- Kanellakis P, et al., *Br J Pharmacol* 160: 2085-2096, 2010
- Jelkmann W, et al., *Crit Rev Oncol/Hematol* 67: 39-61, 2008
- Swift S, et al., *Blood* 115: 4254-4263, 2010
- Lacombe C, et al., *Haematologica* 83: 724-732, 1998
- Bunn HF, et al., *J Exp Biol* 201: 1197-1201, 1998
- Spivak JL, *Lancet* 355: 1707-1712, 2000
- Spivak JL, *Blood* 100: 4272-4290, 2002
- James C, et al., *Nature* 434: 1144-1148, 2005
- Cotes PM, et al., *Nature* 191: 1065-1068, 1961
- de Klerk G, et al., *Blood* 52: 560-568, 1978
- Krystal G, *Exp Hematol* 11: 649-660, 1983
- Kitamura T, et al., *J Cell Physiol* 140: 323-334, 1989
- Damen J, et al., *Blood* 80: 1923-1932, 1992
- Wognum AW, et al., *Blood* 76: 1323-1329, 1990
- Storring PL, et al., *J Endocrinol* 134: 459-484, 1992
- Yuen CT, et al., *Br J Haematol* 121: 511-526, 2003
- Wognum AW, et al., *Blood* 74: 622-628, 1989
- Lasne F, et al., *Nature* 405: 635, 2000
- Skibeli V, et al., *Blood* 98: 3626-3634, 2001
- Reichel, et al., *Drug Test. Analysis* 1: 43-50, 2009
- Egrie JC, et al., *Exp Hematol* 31: 290-299, 2003
- Bunn HF, *Blood* 109: 868-873, 2007
- Leist M, et al., *Science* 305: 239-242, 2004
- Fantacci M, et al., *Proc Natl Acad Sci USA* 103: 17531-17536, 2006
- Wrighton NC, et al., *Science* 273: 458-463, 1996
- Qureshi SA, et al., *Proc Natl Acad Sci USA* 96: 12156-12161, 1999
- Woodburn KW, et al., *Exp Hematol* 35: 1201-1208, 2007
- Goldberg J, et al., *J Am Chem Soc* 124: 544-555, 2002
- Nanako Y, et al., *Blood* 104: 4300-4307, 2004